Tumor necrosis factor-alpha (TNF alpha) has been implicated as a contributing mediator of insulin resistance observed in pathophysiological conditions such as obesity, cancer-induced cachexia, and bacterial infections. Previous studies have demonstrated that TNF alpha confers insulin resistance by promoting phosphorylation of serine residues on insulin receptor substrate 1 (IRS-1), thereby diminishing subsequent insulin-induced tyrosine phosphorylation of IRS-1. However, little is known about which signaling molecules are involved in this process in adipocytes and about the temporal sequence of events that ultimately leads to TNF alpha-stimulated IRS-1 serine phosphorylation. In this study, we demonstrate that specific inhibitors of the MAP kinase kinase (MEK)1/2-p42/44 mitogen-activated protein (MAP) kinase pathway restore insulin signaling to normal levels despite the presence of TNF alpha. Additional experiments show that MEK1/2 activity is required for TNF alpha-induced IRS-1 serine phosphorylation, thereby suggesting a mechanism by which these inhibitors restore insulin signaling. We observe that TNF alpha requires 2.5-4 h to markedly reduce insulin-triggered tyrosine phosphorylation of IRS-1 in 3T3-L1 adipocytes. Although TNF alpha activates p42/44 MAP kinase, maximal stimulation is observed within 10-30 min. To our surprise, p42/44 activity returns to basal levels well before IRS-1 serine phosphorylation and insulin resistance are observed. These activation kinetics suggest a mechanism of p42/44 action more complicated than a direct phosphorylation of IRS-1 triggered by the early spike of TNF alpha-induced p42/44 activity. Chronic TNF alpha treatment (>> 72 h) causes adipocyte dedifferentiation, as evidenced by the loss of triglycerides and down-regulation of adipocyte-specific markers. We observe that this longer term TNF alpha-mediated dedifferentiation effect utilizes alternative, p42/44 MAP kinase-independent intracellular pathways. This study suggests that TNF alpha-mediated insulin resistance, but not adipocyte dedifferentiation, is mediated by the MEK1/2-p42/44 MAP kinase pathway.
机构:
YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT MOL PHARMACOL, BRONX, NY 10461 USAYESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT MOL PHARMACOL, BRONX, NY 10461 USA
Glavy, JS
Horwitz, SB
论文数: 0引用数: 0
h-index: 0
机构:
YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT MOL PHARMACOL, BRONX, NY 10461 USAYESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT MOL PHARMACOL, BRONX, NY 10461 USA
Horwitz, SB
Orr, GA
论文数: 0引用数: 0
h-index: 0
机构:
YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT MOL PHARMACOL, BRONX, NY 10461 USAYESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT MOL PHARMACOL, BRONX, NY 10461 USA
机构:
YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT MOL PHARMACOL, BRONX, NY 10461 USAYESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT MOL PHARMACOL, BRONX, NY 10461 USA
Glavy, JS
Horwitz, SB
论文数: 0引用数: 0
h-index: 0
机构:
YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT MOL PHARMACOL, BRONX, NY 10461 USAYESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT MOL PHARMACOL, BRONX, NY 10461 USA
Horwitz, SB
Orr, GA
论文数: 0引用数: 0
h-index: 0
机构:
YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT MOL PHARMACOL, BRONX, NY 10461 USAYESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT MOL PHARMACOL, BRONX, NY 10461 USA